Merck to Pay $5.9 Mln for Misleading Marketing of Pink Eye Drug: U.S.Merck to Pay $5.9 Mln for Misleading Marketing of Pink Eye Drug: U.S.

Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday. Reuters Health Information
Source: Medscape Ophthalmology Headlines - Category: Opthalmology Tags: Infectious Diseases News Source Type: news